INDIANA HEALTH COVERAGE PROGRAMS (IHCP) PHARMACY BENEFIT VAGINAL ANTIMICROBIALS PRIOR AUTHORIZATION REQUEST FORM



MDwise Fax to: (858) 790-7100 c/o MedImpact Healthcare Systems, Inc. Attn: Prior Authorization Department 10181 Scripps Gateway Court, San Diego, CA 92131 Phone: (800) 788-2949



Today's Date				
Note: This form must be completed by the prescribing provider. **All sections must be completed or the request will be returned**				
Patient's Medicaid # Date of Birth				
Patient's Name		Prescriber's Name		
Prescriber's IN License #		Specialty		
Prescriber's NPI #	ber's NPI #		Prescriber's Signature	
Return Fax #		Return Phone #		
Check box if requesting retro-active PA		Date(s) of service requested for retro-active eligibility (if applicable):		
Note: Submit PA requests for retroactive claims (dates of service prior to eligibility determination, but within established eligibility timelines) with dates of service prior to 30 calendar days of submission separately from current PA requests (dates of service 30 calendar days or less and going forward).				
Requested Medication	Strength		Dosage Regimen	
PA Requirements for BREXAFEMME (ibrexafungerp):				
One of the following diagnoses:				
☐ Diagnosis of acute vulvovaginal candidiasis				
☐ Diagnosis of recurrent vulvovaginal candidiasis (must provide documentation of 3 or more episodes of vulvovaginal candidiasis within the past year)				
2. For members less than 18 years of age: provider attests member is postmenarchal Yes No				
2. For members less than 18 years of a	ge: provide	er attests me	ember is postmenarchal □ Yes □ No	
Provider printed name and signature:		er attests me	ember is postmenarchal □ Yes □ No	
Provider printed name and signature:	ncy test wit	hin the past	: 30 days attached ☐ Yes ☐ No	
Provider printed name and signature: 3. Documentation of a negative pregnar 4. Member has a trial and failure history	ncy test wit	hin the past	: 30 days attached ☐ Yes ☐ No	

CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.

04.01.2023 Page 1

PA Requirements for VIVJOA (oteseconazole):				
1.	Diagnosis of recurrent vulvovaginal candidiasis ☐ Yes ☐ No			
	Note: provide documentation of 3 or more episodes of vulvovaginal candidiasis experienced by member within the past year			
2.	Member is 18 years of age or older ☐ Yes ☐ No			
3.	Provider attests member is not considered to be of reproductive potential $\ \square$ Yes $\ \square$ No			
4.	Member has a trial and failure history of oral fluconazole within the past year $\ \square$ Yes $\ \square$ No			

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.

RXP0024 (4/23) Page 2 04.01.2023